Clinical trial origAMI-2
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Cancers | |
---|---|
Organ | Colon |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Janssen Cilag |
EudraCT Identifier | 2024-513852-13-00 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06662786 |
Last update |